Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.

被引：10
|
作者：
Agarwal, Archana
Pond, Gregory Russell
Curran, Catherine
Nassar, Amin
Nuzzo, Pier Vitale
Kumar, Vivek
McGregor, Bradley Alexander
Wei, Xiao X.
Harshman, Lauren Christine
Choueiri, Toni K.
Kilbridge, Kerry L.
Sonpavde, Guru
机构：
[1] St Elizabeths Med Ctr, Dana Farber Canc Inst, Brighton, MA USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Lank Ctr Genitourinary Malignancy, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, Dept Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    MODERN PATHOLOGY, 2016, 29 : 272A - 272A
  • [32] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    LABORATORY INVESTIGATION, 2016, 96 : 272A - 272A
  • [33] PD1 and PD-L1 in ependymoma might not be therapeutic targets
    Dumont, Benoit
    Forest, Fabien
    Dal Col, Pierre
    Karpathiou, Georgia
    Stephan, Jean-Louis
    Vassal, Francois
    Peoc'h, Michel
    CLINICAL NEUROPATHOLOGY, 2017, 36 (02) : 90 - 92
  • [34] Differential expressions of PD-1, PD-L1, and PD-L2 between the primary and metastatic sites in renal cell carcinoma.
    Zhang, Xingming
    Shen, Pengfei
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI).
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Ostrovnaya, Irina
    Li, Han
    Lee, Chung-Han
    Funt, Samuel Aaron
    Callahan, Margaret K.
    Iyer, Gopa
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Selection of PD1/PD-L1 X-Aptamers
    Wang, Hongyu
    Lam, Curtis H.
    Li, Xin
    West, Derek L.
    Yang, Xianbin
    BIOCHIMIE, 2018, 145 : 125 - 130
  • [37] Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
    Brancatella, Alessandro
    Lupi, Isabella
    Montanelli, Lucia
    Ricci, Debora
    Viola, Nicola
    Sgro, Daniele
    Antonangeli, Lucia
    Sardella, Chiara
    Brogioni, Sandra
    Piaggi, Paolo
    Molinaro, Eleonora
    Bianchi, Francesca
    Aragona, Michele
    Antonuzzo, Andrea
    Sbrana, Andrea
    Lucchesi, Maurizio
    Chella, Antonio
    Falcone, Alfredo
    del Prato, Stefano
    Elisei, Rossella
    Marcocci, Claudio
    Caturegli, Patrizio
    Santini, Ferruccio
    Latrofa, Francesco
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (09)
  • [38] PD1/PD-L1 Axis in Uro-oncology
    Junker, Kerstin
    Eckstein, Markus
    Fiorentino, Michelangelo
    Montironi, Rodolfo
    CURRENT DRUG TARGETS, 2020, 21 (13) : 1293 - 1300
  • [39] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [40] Acrodermatitis continua of Hallopeau upon PD-L1 therapy for metastatic urothelial carcinoma
    Ickrath, Katrin
    Fleissner, Janik
    Egenolf, Timo
    Schmieder, Astrid
    Kerstan, Andreas
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (03) : 296 - 298
12345